Brevan Howard Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Brevan Howard Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$303K	Sell	8,131 -1,124	-12%	-$36.3K	﹤0.01%	1707
2026 Q1	$294K	Buy	+9,255	New	+$252K	﹤0.01%	1637
2025 Q4	–	Sell	-14,362	Closed	-$372K	–	1871
2025 Q3	$372K	Buy	+14,362	New	+$333K	﹤0.01%	1438
2025 Q1	–	Sell	-11,414	Closed	-$288K	–	1193
2024 Q4	$288K	Sell	11,414 -6,401	-36%	-$174K	﹤0.01%	789
2024 Q3	$606K	Buy	17,815 +6,870	+63%	+$262K	﹤0.01%	630
2024 Q2	$405K	Buy	+10,945	New	+$413K	﹤0.01%	677

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's CLDX Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Celldex Therapeutics (CLDX) stake by 12% in Q2 2026, selling an estimated $36.3K and leaving 8,131 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #1707.

Brevan Howard Capital Management first reported a position in CLDX in Q2 2024 and has held it in 6 quarters since. The position peaked at $606K in Q3 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Brevan Howard Capital Management held 8,131 shares of Celldex Therapeutics worth $303K as of Q2 2026.
Brevan Howard Capital Management sold 1,124 Celldex Therapeutics shares in Q2 2026, an estimated $36.3K.
Celldex Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1707 holding.
Brevan Howard Capital Management first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Celldex Therapeutics position peaked at $606K in Q3 2024.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.